Medivir AB

Company

Related News

Medivir Raises Capital for MIV-711 LCPD Indication, OI Trial Advances

Aug 02, 2026

Medivir AB completed an oversubscribed share issue to fund MIV-711 for Legg-Calvé-Perthes disease. MIV-711 is advancing to phase II for osteogenesis imperfecta with FDA orphan drug status. Cash runway extends to 2028 and other pipeline programs are progressing.

Medivir Reports 2025 Annual Results with Key Clinical and Financial Milestones

Apr 01, 2026

Medivir's 2025 Annual Report highlights FDA Orphan Drug Designation for MIV-711 in Osteogenesis Imperfecta and promising fostrox liver cancer data showing 13.7-month median survival. The company raised SEK 196 million to fund Phase 2 studies for both programs and reported year-end cash of SEK 119.2 million.